[go: up one dir, main page]

WO2008015383A8 - Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies - Google Patents

Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies Download PDF

Info

Publication number
WO2008015383A8
WO2008015383A8 PCT/GB2007/002755 GB2007002755W WO2008015383A8 WO 2008015383 A8 WO2008015383 A8 WO 2008015383A8 GB 2007002755 W GB2007002755 W GB 2007002755W WO 2008015383 A8 WO2008015383 A8 WO 2008015383A8
Authority
WO
WIPO (PCT)
Prior art keywords
bmp
breast
prostate cancer
cancer therapies
therapies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/002755
Other languages
French (fr)
Other versions
WO2008015383A3 (en
WO2008015383A2 (en
Inventor
Wen Guo Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd, Cardiff University filed Critical University College Cardiff Consultants Ltd
Publication of WO2008015383A2 publication Critical patent/WO2008015383A2/en
Publication of WO2008015383A3 publication Critical patent/WO2008015383A3/en
Anticipated expiration legal-status Critical
Publication of WO2008015383A8 publication Critical patent/WO2008015383A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the role of BMP-9 and/or BMP-10 in the treatment of breast or prostate cancer.
PCT/GB2007/002755 2006-07-29 2007-07-20 Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies Ceased WO2008015383A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0615129.4A GB0615129D0 (en) 2006-07-29 2006-07-29 Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
GB0615129.4 2006-07-29

Publications (3)

Publication Number Publication Date
WO2008015383A2 WO2008015383A2 (en) 2008-02-07
WO2008015383A3 WO2008015383A3 (en) 2008-08-14
WO2008015383A8 true WO2008015383A8 (en) 2009-07-16

Family

ID=37006438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002755 Ceased WO2008015383A2 (en) 2006-07-29 2007-07-20 Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies

Country Status (2)

Country Link
GB (1) GB0615129D0 (en)
WO (1) WO2008015383A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2891010C (en) 2004-07-23 2022-09-20 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
EP1973559B1 (en) 2005-11-23 2013-01-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2415666T3 (en) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIa antagonists for use in the prevention or treatment of breast cancer metastases or bone loss related to breast cancer
TWI782836B (en) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 Variants derived from actriib and uses therefor
CN101687016B (en) 2007-02-09 2014-12-31 阿塞勒隆制药公司 Activin-actriia antagonists and uses for promoting bone growth in cancer patients
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
WO2009084739A1 (en) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Method and pharmaceutical composition for treatment of cancer using bmp10 protein,
WO2009084738A1 (en) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Method and pharmaceutical composition for treatment of cancer using bmp9 protein
ES2949049T3 (en) 2008-08-14 2023-09-25 Acceleron Pharma Inc GDF traps
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
CN104840944A (en) 2009-06-08 2015-08-19 阿塞勒隆制药公司 Methods for increasing thermogenic adipocytes
CN107267520A (en) 2009-06-12 2017-10-20 阿塞勒隆制药公司 The ACTRIIB FC fusion proteins of truncation
JP6267425B2 (en) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド ACTRIIB protein and its variants and uses thereof for utrophin induction for the treatment of muscular dystrophy
KR20130132824A (en) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia binding agents and uses thereof
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP3964224A1 (en) 2012-11-02 2022-03-09 Celgene Corporation Activin-actrii antagonists and uses for use in treating renal disease
CN107135646B (en) 2014-06-13 2022-03-15 阿塞勒隆制药公司 Methods and compositions for treating ulcers
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
ES2946160T3 (en) 2014-12-03 2023-07-13 Celgene Corp Activin-ActRII Antagonists and Uses to Treat Myelodysplastic Syndrome
JP7056932B2 (en) 2015-08-25 2022-04-19 ヒスタイド アクツィエンゲゼルシャフト Compounds for inducing histogenesis and their use
CA2998455A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
EP3906932A3 (en) * 2015-09-17 2021-12-01 Histide AG Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
US20240408175A1 (en) * 2021-10-18 2024-12-12 The Uab Research Foundation Bmp9 or an agonist thereof and its uses related to reducing metastasis of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2226467T5 (en) * 1998-11-13 2009-08-27 Stryker Corporation RELIEF OF THE SYMPTOMS OF CANCER DE PROSTATA.
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
WO2006029406A2 (en) * 2004-09-09 2006-03-16 Stryker Corporation Methods for treating bone tumors using bone morphogenic proteins

Also Published As

Publication number Publication date
WO2008015383A3 (en) 2008-08-14
GB0615129D0 (en) 2006-09-06
WO2008015383A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
WO2008015383A8 (en) Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
IL184617A0 (en) Dr5 antibodies and uses thereof
WO2007127010A3 (en) Diarylthiohydantoin compounds
EP1893196A4 (en) DIARYLHYDANTOINE COMPOUNDS
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
IL199609A0 (en) Antifolate agent combinations in the treatment of cancer
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
WO2009053041A3 (en) Identification of tumor-associated markers for diagnosis and therapy
WO2008089397A3 (en) Adrb2 cancer markers
WO2008150530A3 (en) Cripto binding molecules
PT2101731T (en) Endoxifen for use in the treatment of cancer
IL185463A0 (en) Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
MX2012001513A (en) Use of melanocortins to treat dyslipidemia.
ZA200709542B (en) Combination therapy in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2009074253A3 (en) Clofarabine dietherphospholipid derivatives
WO2008009895A3 (en) Matriptase-2
WO2008061048A3 (en) Methods and compositions for diagnosing and treating prostate cancer
WO2009046123A3 (en) Nlrr-1 antagonists and uses thereof
AU2005339587A8 (en) Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2